283 related articles for article (PubMed ID: 35350597)
41. Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia.
Ruiz-Llorente L; Gallardo-Vara E; Rossi E; Smadja DM; Botella LM; Bernabeu C
Expert Opin Ther Targets; 2017 Oct; 21(10):933-947. PubMed ID: 28796572
[TBL] [Abstract][Full Text] [Related]
42. SMAD4 Prevents Flow Induced Arteriovenous Malformations by Inhibiting Casein Kinase 2.
Ola R; Künzel SH; Zhang F; Genet G; Chakraborty R; Pibouin-Fragner L; Martin K; Sessa W; Dubrac A; Eichmann A
Circulation; 2018 Nov; 138(21):2379-2394. PubMed ID: 29976569
[TBL] [Abstract][Full Text] [Related]
43. Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function.
Mallet C; Lamribet K; Giraud S; Dupuis-Girod S; Feige JJ; Bailly S; Tillet E
Hum Mol Genet; 2015 Feb; 24(4):1142-54. PubMed ID: 25312062
[TBL] [Abstract][Full Text] [Related]
44. Endothelial tip/stalk cell selection requires BMP9-induced β
Ahmed T; Ramonett A; Kwak EA; Kumar S; Flores PC; Ortiz HR; Langlais PR; Hund TJ; Mythreye K; Lee NY
Mol Biol Cell; 2023 Jun; 34(7):ar72. PubMed ID: 37126382
[TBL] [Abstract][Full Text] [Related]
45. Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia.
Zarrabeitia R; Ojeda-Fernandez L; Recio L; Bernabéu C; Parra JA; Albiñana V; Botella LM
Thromb Haemost; 2016 Jun; 115(6):1167-77. PubMed ID: 26818701
[TBL] [Abstract][Full Text] [Related]
46. EPDR1 is a noncanonical effector of insulin-mediated angiogenesis regulated by an endothelial-specific TGF-β receptor complex.
Ahmed T; Flores PC; Pan CC; Ortiz HR; Lee YS; Langlais PR; Mythreye K; Lee NY
J Biol Chem; 2022 Sep; 298(9):102297. PubMed ID: 35872017
[TBL] [Abstract][Full Text] [Related]
47. New insights into BMP9 signaling in organ fibrosis.
Tang N; Rao S; Ying Y; Huang Y
Eur J Pharmacol; 2020 Sep; 882():173291. PubMed ID: 32574673
[TBL] [Abstract][Full Text] [Related]
48. BMP9 and BMP10: Two close vascular quiescence partners that stand out.
Desroches-Castan A; Tillet E; Bouvard C; Bailly S
Dev Dyn; 2022 Jan; 251(1):178-197. PubMed ID: 34240497
[TBL] [Abstract][Full Text] [Related]
49. Bioinformatic analysis of pathogenic missense mutations of activin receptor like kinase 1 ectodomain.
Scotti C; Olivieri C; Boeri L; Canzonieri C; Ornati F; Buscarini E; Pagella F; Danesino C
PLoS One; 2011; 6(10):e26431. PubMed ID: 22028876
[TBL] [Abstract][Full Text] [Related]
50. Rapid Activation of Bone Morphogenic Protein 9 by Receptor-mediated Displacement of Pro-domains.
Kienast Y; Jucknischke U; Scheiblich S; Thier M; de Wouters M; Haas A; Lehmann C; Brand V; Bernicke D; Honold K; Lorenz S
J Biol Chem; 2016 Feb; 291(7):3395-410. PubMed ID: 26677222
[TBL] [Abstract][Full Text] [Related]
51. TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets.
Jonker L
Microcirculation; 2014 Feb; 21(2):93-103. PubMed ID: 25279424
[TBL] [Abstract][Full Text] [Related]
52. Bone Morphogenetic Protein 9 Protects against Neonatal Hyperoxia-Induced Impairment of Alveolarization and Pulmonary Inflammation.
Chen X; Orriols M; Walther FJ; Laghmani EH; Hoogeboom AM; Hogen-Esch ACB; Hiemstra PS; Folkerts G; Goumans MTH; Ten Dijke P; Morrell NW; Wagenaar GTM
Front Physiol; 2017; 8():486. PubMed ID: 28751863
[No Abstract] [Full Text] [Related]
53. Serum/glucocorticoid-regulated kinase 1 as a novel transcriptional target of bone morphogenetic protein-ALK1 receptor signaling in vascular endothelial cells.
Araki M; Hisamitsu T; Kinugasa-Katayama Y; Tanaka T; Harada Y; Nakao S; Hanada S; Ishii S; Fujita M; Kawamura T; Saito Y; Nishiyama K; Watanabe Y; Nakagawa O
Angiogenesis; 2018 May; 21(2):415-423. PubMed ID: 29478089
[TBL] [Abstract][Full Text] [Related]
54. BMP9 (Bone Morphogenetic Protein-9)/Alk1 (Activin-Like Kinase Receptor Type I) Signaling Prevents Hyperglycemia-Induced Vascular Permeability.
Akla N; Viallard C; Popovic N; Lora Gil C; Sapieha P; Larrivée B
Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1821-1836. PubMed ID: 29880487
[TBL] [Abstract][Full Text] [Related]
55. Structural Basis of the Human Endoglin-BMP9 Interaction: Insights into BMP Signaling and HHT1.
Saito T; Bokhove M; Croci R; Zamora-Caballero S; Han L; Letarte M; de Sanctis D; Jovine L
Cell Rep; 2017 May; 19(9):1917-1928. PubMed ID: 28564608
[TBL] [Abstract][Full Text] [Related]
56. The high affinity ALK1-ligand BMP9 induces a hypertrophy-like state in chondrocytes that is antagonized by TGFβ1.
van Caam A; Blaney Davidson E; Garcia de Vinuesa A; van Geffen E; van den Berg W; Goumans MJ; ten Dijke P; van der Kraan P
Osteoarthritis Cartilage; 2015 Jun; 23(6):985-95. PubMed ID: 25681563
[TBL] [Abstract][Full Text] [Related]
57. Pediatric pulmonary arterial hypertension due to a novel homozygous GDF2 missense variant affecting BMP9 processing and activity.
Chomette L; Hupkens E; Romitti M; Dewachter L; Vachiéry JL; Bailly S; Costagliola S; Smits G; Tillet E; Bondue A
Am J Med Genet A; 2023 Aug; 191(8):2064-2073. PubMed ID: 37249087
[TBL] [Abstract][Full Text] [Related]
58. Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development.
Chen H; Brady Ridgway J; Sai T; Lai J; Warming S; Chen H; Roose-Girma M; Zhang G; Shou W; Yan M
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11887-92. PubMed ID: 23812757
[TBL] [Abstract][Full Text] [Related]
59. Hereditary Haemorrhagic Telangiectasia, an Inherited Vascular Disorder in Need of Improved Evidence-Based Pharmaceutical Interventions.
Snodgrass RO; Chico TJA; Arthur HM
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33513792
[TBL] [Abstract][Full Text] [Related]
60. Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?
Bhatt RS; Atkins MB
Clin Cancer Res; 2014 Jun; 20(11):2838-45. PubMed ID: 24714770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
